Anemia and thrombocytopenia are the most commonly reported hematologic adverse events in studies of the JAK2 inhibitor ruxolitinib in patients with myeloproliferative disorders, but rarely lead to treatment discontinuation and counts often stabilize during treatment [28]. The gene discussed is JAK2; the disease is anemia.